¼¼°èÀÇ ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå : °Ë»ç À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð ¹× Á¡À¯À², ¿¹Ãø(2025-2032³â)
Neurogenetic Testing Market, By Test Type, By Technology, By Application, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1629252
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 355 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 7¾ï 8,625¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2025-2032³â¿¡ CAGR 12.2%·Î È®´ë

½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀå ¿ªÇÐ

½Å°æÁúȯ °ü¸®¿¡¼­ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

½Å°æÁúȯ °ü¸®¿¡¼­ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á´Â °³ÀÎÀÇ À¯ÀüÀû ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÏ¿© º¸´Ù Á¤È®Çϰí È¿°úÀûÀÎ °³ÀÔÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ÇåÆÃÅϺ´°ú °°Àº ½Å°æÁúȯÀº À¯ÀüÀû ¿äÀÎÀÇ ¿µÇâÀ» ¹Þ±â ¶§¹®¿¡ ȯÀÚÀÇ À¯ÀüÀÚ ±¸¼ºÀ» ÀÌÇØÇÏ¸é °¡Àå ÀûÇÕÇÑ Ä¡·á¹ýÀ» ã´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº ½ÃÇàÂø¿À¸¦ ÁÙÀ̰í ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ¿Í ȯÀÚµé »çÀÌ¿¡¼­ ¸ÂÃãÇü ÀÇ·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ À¯ÀüÀÚ °Ë»çÀÇ º¸±ÞÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á¾÷°è°¡ º¸´Ù Á¤¹ÐÇÑ ¸ÂÃã ÀǷḦ ÁöÇâÇÔ¿¡ µû¶ó ½Å°æÀ¯ÀüÇÐÀû °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä´Â È®´ëµÇ°í ½Å°æÁúȯÀÇ Á¤¹ÐÄ¡·á°¡ ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀå : ÁÖ¿ä °í·Á»çÇ×

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032) µ¿¾È ¾à 12.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

°Ë»ç À¯Çüº°·Î´Â »êÀü À¯ÀüÀÚ °Ë»ç°¡ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÇ¾ú½À´Ï´Ù.

±â¼úº°·Î´Â Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®(NGS)ÀÌ 2024³â ÁÖ¿ä ±â¼ú·Î ²ÅÇû½À´Ï´Ù.

¿ëµµº°·Î´Â ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÌ 2024³â ÁÖ¿ä ¿ëµµ·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâ 1À§¸¦ ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù.

½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°è ½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀåÀº °Ë»ç À¯Çü, ±â¼ú, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº °Ë»ç À¯Çü¿¡ µû¶ó »êÀü À¯ÀüÀÚ °Ë»ç, ij¸®¾î ½ºÅ©¸®´×, Áø´Ü °Ë»ç, ¿¹Ãø °Ë»çÀÇ ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. »êÀü À¯ÀüÀÚ °Ë»ç´Â ½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀå¿¡¼­ °¡Àå µÎµå·¯Áø ºÎ¹®ÀÔ´Ï´Ù. ÀÌ ºÎ¹®Àº žÆÀÇ À¯Àü¼º Áúȯ Á¶±â ¹ß°ß¿¡ ´ëÇÑ Àνİú ¼ö¿ä Áõ°¡·Î ÀÎÇØ Å« °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »êÀü °Ë»ç´Â ´Ù¿îÁõÈıº, ³¶Æ÷¼º ¼¶À¯Áõ, ±âŸ ½Å°æ°è Áúȯ°ú °°Àº À¯ÀüÀû ÁúȯÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, Ãâ»êÀ» ¾ÕµÐ ºÎ¸ð¿¡°Ô ±ÍÁßÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ºñħ½ÀÀû »êÀü°Ë»ç(NIPT) Áõ°¡¿Í ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÌ·¯ÇÑ °Ë»ç´Â ´õ¿í Ä£¼÷Çϰí Á¤È®ÇØÁö°í ÀÖ½À´Ï´Ù. Á¶±â Áúº´ ¿¹¹æ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ »êÀü À¯ÀüÀÚ °Ë»ç°¡ ³Î¸® äÅÃµÇ¾î ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß´Â ƯÈ÷ °Ë»ç Á¤È®µµ¸¦ ³ôÀÌ°í ±âÁ¸ °Ë»ç¹ý¿¡ µû¸¥ À§ÇèÀ» ÁÙÀÌ´Â Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS) ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ÀÎÇØ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ±â¼úº°·Î Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS), ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR), ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, Çü±¤ in situ hybridization(FISH), ±âŸ·Î ³ª´¹´Ï´Ù. Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)Àº ½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀå¿¡¼­ °¡Àå ÁÖ¸ñ¹Þ´Â ±â¼ú·Î, À¯Àü¹°ÁúÀÇ ³ôÀº 󸮷®, Á¤È®Çϰí È¿À²ÀûÀÎ ºÐ¼®À» ÅëÇØ À¯ÀüÀÚ º¯ÀÌ¿Í °ü·ÃµÈ ½Å°æÁúȯÀ» ½Äº°ÇÒ ¼ö ÀÖ´Â °­·ÂÇÑ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ÇåÆÃÅϺ´°ú °°Àº º¹ÀâÇÑ ½Å°æÁúȯÀÇ Áø´Ü¿¡ ÀÖÀ¸¸ç, ¹æ´ëÇÑ ¾çÀÇ À¯ÀüÀÚ µ¥ÀÌÅ͸¦ ´Ü½Ã°£¿¡ ½ÃÄö½ÌÇÒ ¼ö ÀÖ´Â ´É·ÂÀº À¯ÀüÀÚ °Ë»ç¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×À¸¸ç, NGS´Â °³ÀÎ ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ý¿¡ ÇʼöÀûÀÎ À¯ÀüÀÚ º¯ÀÌ ¹× µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù. NGSÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ´Â ¹è°æ¿¡´Â ºñ¿ë È¿À²¼º, ³ôÀº Á¤È®µµ, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î NGS´Â ¿ìÀ§¸¦ À¯ÁöÇÏ¸ç ½Å°æÀ¯ÀüÇÐÀû Áø´ÜÀÇ ¹Ì·¡¿¡ Áß½ÉÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀå : Áö¿ªº° ºÐ¼®

ºÏ¹Ì´Â ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀåÀÇ ¼±µÎÁÖÀÚÀ̸ç, ±× ÁÖ¿ä ÀÌÀ¯´Â ÷´ÜÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ³ôÀº ÀνÄ, ÁÖ¿ä ±â¾÷ÀÇ °­·ÂÇÑ Á¸Àç°¨ÀÔ´Ï´Ù. ¹Ì±¹Àº À¯ÀüÀÚ °Ë»çÀÇ º¸±Þ°ú ½Å°æÁúȯ¿¡ ´ëÇÑ ¿¬±¸°¡ Ȱ¹ßÇÏ¿© Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. À¯·´Àº ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í À¯ÀüÀÚ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ º¸Á¶±Ý Áõ°¡·Î ÀÎÇØ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çµµ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖÀ¸¸ç, ƯÈ÷ Áß±¹À̳ª Àεµ¿Í °°Àº ±¹°¡¿¡¼­´Â ÀÇ·á ½Ã½ºÅÛÀÇ °³¼±°ú À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿Àº ÀÇ·á ÅõÀÚ Áõ°¡¿Í ÀÇ·á ¼ö¿ä Áõ°¡·Î ÀÎÇØ ÀáÀçÀûÀÎ ½ÃÀåÀ¸·Î Á¡Â÷ ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹¿¡¼­´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, À¯ÀüÀÚ °Ë»çÀÇ º¸±Þ, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ³ôÀº °ü½ÉÀÌ ½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷ ¹× ¿¬±¸±â°üÀÇ Á¸Àç¿Í À¯ÀüÀÚ ¿¬±¸¸¦ Áö¿øÇÏ´Â Á¤ºÎÀÇ ±¸»óÀÌ ÀÌ ½ÃÀåÀÇ ºü¸¥ ¼ºÀå°ú ±â¼ú Çõ½Å¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀå : °æÀï ±¸µµ

½Å°æÀ¯ÀüÇÐ °Ë»ç ½ÃÀå °æÀï ±¸µµ´Â ±âÁ¸ Áø´Ü ´ë±â¾÷°ú À¯ÀüÀÚ °Ë»ç Àü¹® ±â¾÷ÀÌ È¥ÀçµÇ¾î ÀÖ½À´Ï´Ù. ÀÏ·ç¹Ì³ª, ½á¸ðÇǼŻçÀ̾ðƼÇÈ, Äù½ºÆ®´ÙÀֱ̾׳뽺ƽ½º¿Í °°Àº ±â¾÷Àº ±¤¹üÀ§ÇÑ À¯ÀüÀÚ °Ë»ç Æ÷Æ®Æú¸®¿À¿Í °­·ÂÇÑ ¿µ¾÷¸ÁÀ¸·Î ¿ìÀ§¸¦ Á¡Çϰí ÀÖÀ¸¸ç, Fulgent Genetics¿Í GeneDx¿Í °°Àº Áß¼Ò±â¾÷Àº Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®°ú °°Àº Çõ½Å ±â¼úÀ» Ȱ¿ëÇÏ¿© ½Å°æÁúȯÀÇ Á¤¹ÐÁø´ÜÀ» Á¦°øÇÏ´Â Â÷¼¼´ë ½ÃÄö½Ì°ú °°Àº Çõ½Å ±â¼úÀ» Ȱ¿ëÇÏ¿© ½Å°æÁúȯÀÇ Á¤¹ÐÁø´ÜÀ» Á¦°øÇÏ´Â Àü¹® °Ë»ç ¼­ºñ½º¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯ÀüÀÚ °Ë»ç ±â¾÷°ú ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿ÍÀÇ Çù·ÂÀÌ ÁøÇàµÇ¾î °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó °¢ ¾÷üµéÀº À¯ÀüÀÚ °Ë»ç ¿ª·® È®´ë¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, °Ë»ç °á°ú¸¦ °³¼±Çϱâ À§ÇØ ÀΰøÁö´ÉÀ» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. °æÀï ¾Ð·ÂÀº Áö¼ÓÀûÀÎ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ°í ½ÃÀåÀ» ¸Å¿ì ¿ªµ¿ÀûÀ¸·Î ¸¸µé°í ÀÖÀ¸¸ç, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷Àº ºü¸£°Ô ÁøÈ­ÇÏ´Â ½Å°æÀ¯ÀüÇÐ °Ë»ç ºÐ¾ß¿¡¼­ ¹Ì°³Ã´ ±âȸ¸¦ ¸ð»öÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»çÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå ±¸µµ

Á¦7Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå : °Ë»ç À¯Çüº°

Á¦8Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå : ±â¼úº°

Á¦9Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå : ¿ëµµº°

Á¦10Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ½ÃÀå : Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® : ½Å°æÀ¯ÀüÇÐÀû °Ë»ç ¾÷°è

Á¦13Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Neurogenetic Testing Market size was valued at US$ 786.25 Million in 2024, expanding at a CAGR of 12.2% from 2025 to 2032.

The neurogenetic testing market focuses on diagnostic tests that identify genetic variations linked to neurological disorders. These tests are crucial for diagnosing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and various genetic neuropathies. Neurogenetic testing can help in understanding disease progression, selecting appropriate treatments, and predicting risk for family members. The market is driven by advances in genetic research, increasing awareness of personalized medicine, and growing demand for early disease detection. Technological advancements like next-generation sequencing (NGS) are enhancing the accuracy and efficiency of these tests. With a rise in genetic counseling services and healthcare's shift toward precision medicine, the demand for neurogenetic tests is expected to continue growing. The market also faces challenges related to ethical concerns, insurance coverage, and the need for regulation in testing practices.

Neurogenetic Testing Market- Market Dynamics

Increasing demand for personalized medicine in neurological disease management.

The growing demand for personalized medicine in neurological disease management is a key driver for the neurogenetic testing market. Personalized medicine tailors treatments based on individual genetic profiles, allowing for more precise and effective interventions. As neurological conditions like Alzheimer's, Parkinson's, and Huntington's disease are influenced by genetic factors, understanding a patient's genetic makeup helps identify the most suitable treatments. This approach reduces trial-and-error methods, improving patient outcomes. The increasing recognition of the benefits of personalized medicine among healthcare providers and patients has led to more widespread adoption of genetic testing. As the healthcare industry moves toward more targeted and individualized care, the demand for neurogenetic testing is expected to grow, advancing precision therapies for neurological disorders.

Neurogenetic Testing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.2% over the forecast period (2025-2032)

Based on Test Type segmentation, Prenatal Genetic Testing was predicted to show maximum market share in the year 2024

Based on Technology segmentation, Next-Generation Sequencing (NGS) was the leading Technology in 2024

Based on Application segmentation, Alzheimer's Disease was the leading Application in 2024

Based on region, North America was the leading revenue generator in 2024

Neurogenetic Testing Market- Segmentation Analysis:

The Global Neurogenetic Testing Market is segmented based on Test Type, Technology, Application, End-User, and Region.

The market is divided into three categories based on Test Type: Prenatal Genetic Testing, Carrier Screening, Diagnostic Testing, and Predictive Testing. Prenatal Genetic Testing is the most prominent segment in the neurogenetic testing market. This segment has gained significant traction due to increasing awareness and demand for early detection of genetic disorders in unborn children. Prenatal testing helps identify genetic conditions like Down syndrome, cystic fibrosis, and other neurological disorders, providing valuable information for expecting parents. The rise in non-invasive prenatal testing (NIPT) and advancements in technology have made these tests more accessible and accurate. With a growing focus on early disease prevention, prenatal genetic testing is being adopted widely, driving market growth. This segment is expected to maintain its prominence, particularly with the ongoing advancements in next-generation sequencing (NGS) technologies, which improve testing accuracy and reduce risks associated with traditional testing methods.

The market is divided into two categories based on Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, and Fluorescence in situ Hybridization (FISH), Others. Next-Generation Sequencing (NGS) is the most prominent technology in the neurogenetic testing market. NGS allows for high-throughput, accurate, and efficient analysis of genetic material, making it a powerful tool for identifying neurological disorders linked to genetic mutations. Its ability to sequence vast amounts of genetic data in a short time has revolutionized genetic testing, particularly in diagnosing complex neurological diseases like Alzheimer's, Parkinson's, and Huntington's disease. NGS provides detailed insights into genetic variations and mutations that are critical for personalized treatment approaches. The growing adoption of NGS is driven by its cost-effectiveness, high accuracy, and the increasing demand for precision medicine. With continuous advancements, NGS is expected to maintain its dominance and play a central role in the future of neurogenetic diagnostics.

Neurogenetic Testing Market- Geographical Insights

North America is the leading region in the neurogenetic testing market, primarily due to advanced healthcare infrastructure, high awareness about genetic testing, and a strong presence of key companies. The U.S. is a major contributor, with widespread adoption of genetic testing and robust research in neurological diseases. Europe follows closely, driven by the growing focus on personalized medicine and increasing government funding for genetic research. The Asia-Pacific region is also witnessing significant growth, particularly in countries like China and India, where improving healthcare systems and rising awareness about genetic testing are fueling demand. Additionally, Latin America and the Middle East are gradually emerging as potential markets due to increasing healthcare investments and rising healthcare needs.

In the United States, the neurogenetic testing market is driven by advanced healthcare infrastructure, widespread adoption of genetic testing, and a strong focus on personalized medicine. The presence of leading companies and research institutions, along with government initiatives supporting genetic research, contributes to the rapid growth and innovation in this market.

Neurogenetic Testing Market- Competitive Landscape:

The competitive landscape of the neurogenetic testing market is shaped by a mix of established diagnostic giants and specialized genetic testing firms. Companies like Illumina, Thermo Fisher Scientific, and Quest Diagnostics dominate with extensive genetic testing portfolios and strong distribution networks. Smaller players such as Fulgent Genetics and GeneDx focus on specialized testing services, leveraging innovative technologies like next-generation sequencing to offer precise diagnostics for neurological disorders. The market is also witnessing increasing collaboration between genetic testing firms and healthcare providers, enhancing the accessibility of testing. With the rising demand for personalized medicine, players are investing in expanding their genetic testing capabilities and integrating artificial intelligence for improved test results. The competitive pressure encourages continuous innovation, making the market highly dynamic, with new entrants exploring untapped opportunities in the rapidly evolving field of neurogenetic testing.

Recent Developments:

In February 2024, Sysmex Corporation and Hitachi High-Tech Corporation announced a collaboration to develop genetic testing systems utilizing capillary electrophoresis sequencers (CE sequencers). This partnership aims to expand its presence in untapped economies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROGENETIC TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL NEUROGENETIC TESTING MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEUROGENETIC TESTING MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEUROGENETIC TESTING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEUROGENETIC TESTING MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL NEUROGENETIC TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Neurogenetic Testing Market Overview

2. Executive Summary

3. Neurogenetic Testing Key Market Trends

4. Neurogenetic Testing Industry Study

5. Neurogenetic Testing Market: Impact of Escalating Geopolitical Tensions

6. Neurogenetic Testing Market Landscape

7. Neurogenetic Testing Market - By Test Type

8. Neurogenetic Testing Market - By Technology

9. Neurogenetic Testing Market - By Application

10. Neurogenetic Testing Market - By End-User

11. Neurogenetic Testing Market- By Geography

12. Key Vendor Analysis- Neurogenetic Testing Industry

13. 360 Degree AnalystView

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â